బయోకెమిస్ట్రీ & అనలిటికల్ బయోకెమిస్ట్రీ

నైరూప్య

Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins

Scott Nadeau, Wei An, Nick Palermo, Dan Feng, Gulzar Ahmad, Lin Dong, Gloria E. O. Borgstahl, Amarnath Natarajan, Mayumi Naramura, Vimla Band and Hamid Band

Members of the Cbl protein family (Cbl, Cbl-b, and Cbl-c) are E3 ubiquitin ligases that have emerged as critical negative regulators of protein tyrosine kinase (PTK) signaling. This function reflects their ability to directly interact with activated PTKs and to target them as well as their associated signaling components for ubiquitination. Given the critical roles of PTK signaling in driving oncogenesis, recent studies in animal models and genetic analyses in human cancer have firmly established that Cbl proteins function as tumor suppressors. Missense mutations or small in-frame deletions within the regions of Cbl protein that are essential for its E3 activity have been identified in nearly 5% of leukemia patients with myelodysplastic/myeloproliferative disorders. Based on evidence from cell culture studies, in vivo models and clinical data, we discuss the potential signaling mechanisms of mutant Cbl-driven oncogenesis. Mechanistic insights into oncogenic Cbl mutants and associated animal models are likely to enhance our understanding of normal hematopoietic stem cell homeostasis and provide avenues for targeted therapy of mutant Cbl-driven cancers